Literature DB >> 12910252

The role of Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8 regulator of transcription activation (RTA) in control of gene expression.

John T West1, Charles Wood.   

Abstract

The mechanisms that control the replication state, latency versus lytic, of human herpesviruses have been under intense investigations. Here we summarize some of the recent findings that help define such mechanisms for Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8 (KSHV/HHV-8). For HHV-8, the viral regulator of transcription activation (RTA) is a key mediator of the switch from latency to lytic gene expression in infected cells. RTA is necessary and sufficient to drive HHV-8 lytic replication and the production of viral progeny. The RTA is an immediate-early gene product, it is the initial activator of expression of a multitude of viral and cellular genes that have been implicated in the replication of HHV-8 and pathogenesis of KS. Interactions of RTA with a number of viral promoters, and with a number of transcription factors or transcriptional co-activators are highlighted. Modulation of transactivation, through alternate RTA-protein, or RTA-promoter interactions, is hypothesized to participate in the selective tissue tropism and differential pathogenesis observed in KS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12910252     DOI: 10.1038/sj.onc.1206555

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  63 in total

1.  Accumulation of heterochromatin components on the terminal repeat sequence of Kaposi's sarcoma-associated herpesvirus mediated by the latency-associated nuclear antigen.

Authors:  Shuhei Sakakibara; Keiji Ueda; Ken Nishimura; Eunju Do; Eriko Ohsaki; Toshiomi Okuno; Koichi Yamanishi
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

2.  Viral factors reveal a role for REF/Aly in nuclear RNA stability.

Authors:  Sarah H Stubbs; Olga V Hunter; Ashley Hoover; Nicholas K Conrad
Journal:  Mol Cell Biol       Date:  2012-01-30       Impact factor: 4.272

Review 3.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

4.  Ex vivo stimulation of B cells latently infected with gammaherpesvirus 68 triggers reactivation from latency.

Authors:  Janice M Moser; Jason W Upton; Kathleen S Gray; Samuel H Speck
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

5.  A gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but fails to vaccinate against a wild-type virus challenge.

Authors:  Janice M Moser; Michael L Farrell; Laurie T Krug; Jason W Upton; Samuel H Speck
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus transactivator RTA promotes degradation of the repressors to regulate viral lytic replication.

Authors:  Zhilong Yang; Zhangcai Yan; Charles Wood
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

7.  The interaction between KSHV RTA and cellular RBP-Jkappa and their subsequent DNA binding are not sufficient for activation of RBP-Jkappa.

Authors:  Anil Papugani; Tricia Coleman; Clinton Jones; Luwen Zhang
Journal:  Virus Res       Date:  2007-09-11       Impact factor: 3.303

8.  Role of protein kinase C delta in reactivation of Kaposi's sarcoma-associated herpesvirus.

Authors:  Einat Deutsch; Adina Cohen; Gila Kazimirsky; Sara Dovrat; Hadara Rubinfeld; Chaya Brodie; Ronit Sarid
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

9.  Wide-scale use of Notch signaling factor CSL/RBP-Jkappa in RTA-mediated activation of Kaposi's sarcoma-associated herpesvirus lytic genes.

Authors:  Linda M Persson; Angus C Wilson
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

10.  Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by alpha interferon and phosphonoformic acid.

Authors:  Laurie T Krug; Veronika P Pozharskaya; Yimin Yu; Naoki Inoue; Margaret K Offermann
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.